Editorial by Walsh, Garry M
211
EDITORIAL FOREWORD
Volume 3 • Number 2 • 2007
Therapeutics and Clinical Risk Management 2007:3(2) 211–212
© 2007 Dove Medical Press Limited. All rights reserved
Editorial
Asthma is now one of the most common chronic diseases in westernized countries and 
is characterized by reversible airway obstruction, bronchial hyperresponsiveness, and 
airway inﬂ  ammation. Key pathological features include: inﬁ  ltration of the airways by 
activated lymphocytes and eosinophils; damage to, and loss of, the bronchial epithe-
lium; mast cell degranulation; mucous gland hyperplasia; and collagen deposition in 
the epithelial sub-basement membrane area. Presently, antiinﬂ  ammatory therapy in 
asthma is largely reliant on corticosteroids, particularly in their inhaled form, and their 
use is associated with a striking reduction in the numbers of activated eosinophils, mast 
cells, and T cells in vivo. For the majority of patients, corticosteroids are effective at 
suppressing airway inﬂ  ammation and the associated re-modelling of the airways that 
leads to progressive and irreversible loss of lung function. In his overview, Olof Selroos 
(2007) describes the various treatment options for the use of inhaled corticosteroids 
therapy in asthma with an emphasis on Symbicort SMART® (Symbicort Maintenance 
and Reliever Therapy). This consists of a budesonide–formoterol combination enabling 
patients to use one inhaler for both maintenance and reliever therapy. Beneﬁ  ts of the 
use of a combined corticosteroids–long-acting β2-agonist bronchodilator in the one 
inhaler include reductions in the rate of asthma exacerbations and maintenance of day-
to-day asthma control at a reduced load of corticosteroids when compared with higher 
ﬁ  xed maintenance doses of combination inhalers. However, although corticosteroids 
are usually efﬁ  cacious, they may not be of beneﬁ  t to patients with severe asthma who 
experience virally-induced exacerbations of their disease. Their use also raises con-
cerns regarding side-effects and compliance particularly in children and adolescents. 
Furthermore, even in cases of good compliance for corticosteroid usage, patients with 
moderate and severe asthma may experience signiﬁ  cant residual symptoms including 
exacerbations of their disease that in some cases can be life-threatening (Holtzman 
2003). There remains an urgent need for the development of more targeted, effective, 
and safe therapy for asthma. 
Asthma pathology is associated with the release of myriad pro-inﬂ  ammatory 
substances including lipid mediators, inﬂ  ammatory peptides, chemokines, cytokines, 
and growth factors. As many mediators contribute to the pathophysiology of asthma, 
the development of speciﬁ  c antagonists directed at these substances represents an 
attractive target for inﬂ  ammation resolution. However, it is unlikely that a single 
antagonist will have a major clinical effect compared with nonspeciﬁ  c agents such as 
corticosteroids. Indeed, strategies to block a single mediator such as platelet-activating 
factor antagonists, thromboxane inhibitors, and bradykinin antagonists have all proved 
to be disappointing. However some speciﬁ  c inhibitors, notably cysteinyl leukotriene 
antagonists, have had promising clinical effects (Walsh 2005). The cysteinyl leukotri-
ene receptor antagonists were the ﬁ  rst new class of anti-asthma drugs to be introduced 
in the last 30 years and are now an established part of the asthma armamentarium. 
Overall, they are less effective than inhaled corticosteroids, but some patients show 
a striking improvement and a corticosteroid-sparing effect has been demonstrated. It 
is of interest therefore that Lagos and Marshall (2007) have reviewed the use of the 
cysteinyl leukotriene antagonist montelukast in the treatment of seasonal allergic rhi-
nitis (SAR). The authors conclude that montelukast confers comparable beneﬁ  t to that 
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given by antihistamines in SAR and that both drugs are more 
efﬁ  cacious when given together. In some cases the efﬁ  cacy 
of combined therapy in the treatment of SAR approaches 
that of nasal steroids. However the author acknowledges 
that more research is required in order to determine the ef-
ﬁ  cacy of montelukast in treating perennial allergic rhinitis 
but early indications do indicate a likely favorable proﬁ  le. 
Finally, montelukast may be the treatment of choice for SAR 
in those patients with concomitant asthma. 
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